Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Halozyme Therapeutics Trading Down 0.4 %

Shares of NASDAQ HALO traded down $0.22 during midday trading on Thursday, reaching $57.70. The company had a trading volume of 879,987 shares, compared to its average volume of 1,292,471. The stock has a market cap of $7.11 billion, a PE ratio of 16.82, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $65.53. The firm’s fifty day moving average price is $54.08 and its 200-day moving average price is $54.71. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors have recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust raised its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on HALO. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright raised their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Benchmark reiterated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.